WASHINGTON, June 22 /PRNewswire-USNewswire/ -- Pharmaceutical Research and Manufacturers of America (PhRMA) President & CEO Billy Tauzin today issued the following statement regarding today's AARP-White House press conference on health care reform:
"With the strong support of AARP, we believe this agreement will be looked back in time as a momentum changer in the legislative efforts to reform our troubled health care system. Our $80 billion pledge toward that goal represents a huge financial commitment by America's pharmaceutical research and biotechnology companies. But we have a shared vision: every single person in America, regardless of their income, should have access to affordable, high-quality health care coverage and services.
"Even though we have had policy disagreements in the past, this is an historic coming-together moment. AARP, the largest advocacy organization on behalf of American seniors, clearly recognizes the importance of innovative, cutting-edge medicines to the lives of patients everywhere.
"And we recognize that a medicine which sits on a shelf out of reach of patients financially doesn't do anyone any good. Working together with President Obama, Senate Finance Committee Chairman Baucus and other congressional leaders, we have now taken an important first step toward achieving comprehensive health care reform this year.
"In life, we get precious few opportunities to fundamentally improve the lives of people all across our great nation. We are proud to join AARP, the White House and Congress in seizing that moment today."
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $50.3 billion in 2008 in discovering and developing new medicines. Industry-wide research and investment reached a record $65.2 billion in 2008.
|SOURCE Pharmaceutical Research and Manufacturers of America|
Copyright©2009 PR Newswire.
All rights reserved